Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

Leukemia. 2011 May;25(5):872-4. doi: 10.1038/leu.2011.4. Epub 2011 Feb 15.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / pharmacokinetics
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Drug Resistance, Neoplasm*
  • Drug Therapy, Combination
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / immunology
  • Multiple Myeloma / metabolism
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / metabolism
  • Pyrazines / pharmacokinetics
  • Pyrazines / therapeutic use*
  • Receptor, IGF Type 1 / immunology*
  • Survival Rate
  • Tissue Distribution
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Receptor, IGF Type 1
  • AVE1642